Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
111. |
ECCT/16/12/01 | The Partners Scale-Up Project Animplementation project to scale-up delivery of antiretroviral-based HIV-1 prevention amongKenyan HIV-1 serodiscordant couples. |
Principal Investigator(s) 1. Prof. Elizabeth Ann Bukusi Site(s) in Kenya 1. KISUMU SITE (Kisumu county) 2. Thika Site (Kiambu county) |
View |
112. |
ECCT/19/02/01 | DANCE Study An Open-Label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-Drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-Infected Adolescents, ≥12 To <18 Years of Age who Weigh at Least 40 Kg. |
Principal Investigator(s) 1. Fredrick Odhiambo Otieno 2. Isaac Tsikhutsu Site(s) in Kenya 1. Nyanza Reproductive Health Society (Kisumu county) 2. Kenya Medical Research Institute (Kisumu county) 3. Kenya Medical Research Institute, Walter Reed Project (Kericho county) |
View |
113. |
ECCT/13/03/02 | An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples The Partners PrEP Study Demonstration Project |
Principal Investigator(s) 1. DR.ELIZABETH ANNE BUKUSI ELIZABETH ANNE BUKUSI Site(s) in Kenya 1. THIKA (Nairobi City county) |
View |
114. |
ECCT/12/08/01 | Partners Demonstration Project An open-label, pilot demonstration and evaluation project of antiretrovira-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples. |
Principal Investigator(s) 1. Dr. Nelly Rwamba Mugo Site(s) in Kenya 1. Partners in Prevention, Thika Site (Kiambu county) 2. Partners in Prevention, Kisumu Site (Kisumu county) |
View |
115. |
ECCT/19/04/03 | Phase III pediatric study with the L-PZQ ODTs An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®) |
Principal Investigator(s) 1. Maurice Reuben Odiere Site(s) in Kenya KEMRI-Centre for Global Health Research (CGHR) |
View |